

# FOXO3a pSer294 (human; residues 289-298), pAb

Alternate Names: Foxo3, Forkhead in Rhabdosarcoma-Like 1; FKHL1

Cat. No. 68-0038-100  
Lot. No. 30277

Quantity: 100 µg  
Storage: -20°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS

Page 1 of 2

This antibody was developed and validated by the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (University of Dundee, Dundee, UK).

## Background

Protein ubiquitylation and protein phosphorylation are two major post-translational modifications that regulate the functions of proteins in eukaryotic cells. However, these modifications do not operate independently of one another, but are frequently interlinked to enable biological processes to be controlled in a more complex and sophisticated manner. Studying how protein phosphorylation events control the ubiquitin system and how ubiquitylation regulates protein phosphorylation has become a focal point of the study of cell regulation and human disease. Cloning of Forkhead Box O3a (FOXO3a) was first described by Anderson *et al.* (1998). FOXO3a belongs to the forkhead family of transcription factors, it is a member of the O subclass which can be characterized by a distinct fork head DNA-binding domain. Three other FOXO family members exist in humans, FOXO1, FOXO4 and FOXO6. These transcription factors share the ability to be inhibited and translocated out of the nucleus upon phosphorylation by enzymes such as Akt/PKB from the PI3K signaling pathway (Brunet *et al.*, 1999; Skurk *et al.*, 2005). FOXO3a has been shown to upregulate pro-apoptotic genes, such as Bim and PUMA, or down-regulate anti-apoptotic genes such as FLIP (Ekoff *et al.*, 2014; Skurk *et al.*, 2005). Deregulation of FOX family transcription fac-

Continued on page 2

## Physical Characteristics

Quantity: 100 µg

Formulation: phosphate-buffered saline

Concentration: to be provided on shipping

Specificity: detects FOXO3a at ~82-97 kDa

Source: sheep polyclonal antibody

Reactivity: human; other species not tested

Immunogen: human FOXO3a (residues 289-298) [SKWPG(pS)PTSR]

Stability/Storage: 12 months at -20°C; aliquot as required

Purification: affinity-purified against phosphopeptide

## Research Applications and Quality Assurance


### Western Immunoblotting:

use 1 µg/ml; add 10 µg of the non-phosphorylated form of the peptide immunogen (Cat# 68-1001-001 provided) to your immunoblotting incubation per 1 µg of polyclonal antibody in order to deplete any non-phospho specific polyclonal antibodies present.

### Immunoprecipitation:

not tested

|          |   |   |   |   |   |   |
|----------|---|---|---|---|---|---|
| FOXO3a   | - | - | + | + | + | + |
| Arsenite | - | - | - | - | + | + |
| PP1γ     | - | + | - | + | - | + |



IB: FOXO3a pSer294

### Western Blotting Analysis:

FLAG-FOXO3a was transfected into HEK293 cells and the cells were serum starved overnight and then stimulated with or without arsenite (0.5 M) for 60 mins. Immunoprecipitation was subsequently performed from 100 µg cell lysate using a commercially available anti-FLAG antibody. The immunoprecipitate was treated +/- 1 mU of PP1γ for 30 mins at 30°C. FOXO3a pSer294 was subsequently detected by Western Blot using the anti-FOXO3a pSer294 antibody (Cat# 68-0038-100).



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

International: +1-617-245-0020  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT


International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0



## FOXO3a pSer294 (human; residues 289-298), pAb

Alternate Names: Foxo3, Forkhead in Rhabdosarcoma-Like 1; FKHL1

Cat. No. 68-0038-100  
Lot. No. 30277

Quantity: 100 µg  
Storage: -20°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

CERTIFICATE OF ANALYSIS

Page 2 of 2

## Background

Continued from page 1

tors (including FOXO3a) has a crucial role in the development and progression of cancer, and as such have been evaluated as direct and indirect targets for therapeutic intervention, as well as biomarkers for predicting and monitoring treatment responses. (Myatt *et al.*, 2007).

### Antibody Production:

Anti-FOXO3a pSer294 (human) polyclonal antibody was raised in sheep against FOXO3a pSer294 (residues 289-298 of human FOXO3a; Ser294 phosphorylated). The antibodies were purified by the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU, University of Dundee, Dundee, U.K.) by affinity purification of the anti-FOXO3a pAbs from the sheep serum using a GST-tagged antigen-agarose column. Anti-FOXO3a pSer294 (human) pAb was sourced by Ubiquigent directly from the MRC-PPU.

Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofers S, Pimentel D, Lecker S, Taegtmeier H, Goldberg AL, Walsh K (2005) The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. *J Biol Chem* 280, 20814-20823.

### Application Reference:

Ho KK, McGuire VA, Koo CY, Muir KW, de Olano N, Maifoshie E, *et al.* (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. *J Biol Chem* 287, 1545-1555.

### General References:

Anderson M J, Viars CS, Czekay S, Cavenee W K, Arden K C. (1998) Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. *Genomics* 47, 187-199.

Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96, 857-68.

Ekoff M, Kaufmann T, Engström M, Motoyama N, Villunger A, Jönsson JI, Strasser A, Nilsson G (2007). The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. *Blood* 110, 3209-17.

Myatt SS, Lam EW (2007) The emerging roles of forkhead box (Fox) proteins in cancer. *Nat Rev Cancer* 7, 847-59.

Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, Walsh K (2004). The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. *J Biol Chem* 279, 1513-25.



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

International: +1-617-245-0020  
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)  
Email: sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)  
US/Canada: +1-617-245-0020 (9AM-5PM UTC)  
Email: tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0